AT&T Inc (TBB)vsVertex Pharmaceuticals Inc (VRTX)

TBB

AT&T Inc

NYSE

$21.58

-0.05%

· Cap: $132.50B

VRTX

Vertex Pharmaceuticals Inc

NASDAQ

$454.97

+1.42%

HEALTHCARE · Cap: $113.95B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

VRTX leads profitability with a 32.9% profit margin vs 0.0%. TBB trades at a lower P/E of 4.2x. VRTX earns a higher WallStSmart Score of 66/100 (B-).

TBB

Avoid

out of 100

Grade: F

Growth: 6.0Profit: 4.5Value: 6.7Quality: 5.0

Piotroski: 5/9Altman Z: 0.87

VRTX

Strong Buy

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0

Piotroski: 3/9Altman Z: 3.62

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for TBB.

VRTXUndervalued (+36.5%)

Margin of Safety

+36.5%

Fair Value

$716.04

Current Price

$454.97

$261.07 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TBB3 strengths · Avg: 9.0/10

P/E RatioValuation

4.2x10/10

Attractively priced relative to earnings

Market CapQuality

$132.50B9/10

Large-cap with strong market position

Free Cash FlowQuality

$4.54B8/10

Generating 4.5B in free cash flow

VRTX6 strengths · Avg: 9.5/10

Profit MarginProfitability

32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability

39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth

3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality

$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability

22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth

0.219/10

Conservative balance sheet, low leverage

Areas to Watch

TBB4 concerns · Avg: 3.5/10

Revenue GrowthGrowth

0.0%4/10

0.0% revenue growth

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Operating MarginProfitability

0.0%3/10

Operating margin of 0.0%

VRTX3 concerns · Avg: 3.7/10

PEG RatioValuation

2.194/10

Expensive relative to growth rate

P/E RatioValuation

29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality

3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : TBB

The strongest argument for TBB centers on P/E Ratio, Market Cap, Free Cash Flow.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : TBB

The primary concerns for TBB are Revenue Growth, EPS Growth, Profit Margin. Debt-to-equity of 1.57 is elevated, increasing financial risk.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

TBB profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

VRTX is growing revenue faster at 9.5% — sustainability is the question.

TBB generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor sector industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VRTX scores higher overall (66/100 vs 25/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AT&T Inc

· · USA

AT&T Inc. provides digital entertainment communications and services. The company is headquartered in Dallas, Texas.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?

Full TBB Analysis →Full VRTX Analysis →